19.74
19.74 (0%)
As of Feb 14, 2025
Kiniksa Pharmaceuticals, Ltd. [KNSA]
Source:
Company Overview
Kiniksa Pharmaceuticals International, Plc is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.
| Country | United States |
| Headquarters | hamilton |
| Phone Number | 7814399100 |
| Industry | manufacturing |
| CEO | Sanj K. Patel |
| Website | www.kiniksa.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $423.2 |
| Operating Profit | $-45.6 |
| Net Income | $-43.2 |
| Net Cash | $75.6 |
Profit Ratios
| Gross Margin | $362.3 |
| Operating Margin | -10.8 |
| Profit as % of Revenues | -838.9% |
| Profit as % of Assets | -7.8% |
| Profit as % of Stockholder Equity | -9.9% |
Management Effectiveness
| Return on Equity | -9.9% |
| Return on Assets | -7.4% |
| Turnover Ratio | 76.5% |
| EBITA | $-45.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $580.6 |
| Total Liabilities | $142.1 |
| Operating Cash Flow | $25.7 |
| Investing Cash Flow | $37.7 |
| Financing Cash Flow | $12.3 |
